Summary of key achievements and milestones

2004

         Delivered the 6 compounds as specified to Fujisawa

         PG2 patent granted in China (4Q)

         PG2 launched in China (4Q)

2003

         Sign extension Agreement with Fujisawa (4Q)

         Start Phase I Clinical Trials for TriptoSar with PFM in Europe (4Q)  

2002

         Enroll patients for Phase I Clinical Trials in USA for TriptoSar (2Q)

         Sign Option Agreement with Fujisawa regarding WilGraf (3Q)

         Sign license agreement with PFM regarding TriptoSar (4Q)  

2001

         PG2 Clinical Trial initiated in Taiwan (2Q)

         NDA approval for PG2 in PRC (3Q)

         Signature of out-licensing letter of intent with regards to TriptoSar (2Q)

         IND filing for TriptoSar in USA (3Q)  

2000

         Creation of a manufacturing JV of Orchid Sarl in Tianjin (1Q)

         PG2-2000 Provisional Patent filed (2Q) in U.S.

         PG2 PCT Patent filed (2Q) in U.S.  

1999

         Significant new funding (1Q)

         Creation of PhytoHealth in Taiwan (1Q)

         PG2 Provisional Patent filed (2Q)

         PG2 clinical trials completed in PRC (4Q)  

1998

         PCT Patent Application filed for TriptoSar

         US Patent filed for WilGraf  

1997

         Pharmagenesis, Inc. received patent in U.S. on PG490-88 (3Q)

         Clinical study on PG2 in China is initiated (3Q)  

 

SAB ] [ Milestones ] Business Dev ] Press Releases ]

Home ] Management ] R&D ] IP ] Contact ] Site Map ]